Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond

References

• MouraliJBénardALourençoFCAnaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavageMol Cell Biol2006266209622216880530
   PubMed Web of Science ®Google Scholar
• MehlenPBredesenDEDependence receptors: from basic research to drug developmentSci Signal20114mr221266712
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature200744856156617625570
   PubMed Web of Science ®Google Scholar
• KoivunenJPMermelCZejnullahuKEML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancerClin Cancer Res2008144275428318594010
   PubMed Web of Science ®Google Scholar
• InamuraKTakeuchiKTogashiYEML4-ALK fusion is linked to histological characteristics in a subset of lung cancersJ Thorac Oncol20083131718166835
   PubMed Web of Science ®Google Scholar
• WongDWLeungELSoKKUniversity of Hong Kong Lung Cancer Study GroupThe EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRASCancer20091151723173319170230
   PubMed Web of Science ®Google Scholar
• BolandJMErdoganSVasmatzisGAnaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional upregulation in non-small cell lung carcinomasHum Pathol2009401152115819386350
   PubMed Web of Science ®Google Scholar
• RodigSJMino-KenudsonMDacicSUnique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western populationClin Cancer Res2009155216522319671850
   PubMed Web of Science ®Google Scholar
• TakahashiTSonobeMKobayashiMClinicopathologic features of nonsmall-cell lung cancer with EML4-ALK fusion geneAnn Surg Oncol20101788989720183914
   PubMed Web of Science ®Google Scholar
• InamuraKTakeuchiKTogashiYEML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onsetModern Pathol2009224508515
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancerClin Cancer Res20091593143314919383809
   PubMed Web of Science ®Google Scholar
• RikovaKGuoAZengQGlobal survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancerCell200713161190120318083107
   PubMed Web of Science ®Google Scholar
• LindemanNICaglePTBeasleyMBMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular PathologyArch Pathol Lab Med2013137682886023551194
   PubMed Web of Science ®Google Scholar
• DemidovaIBarinovASavelovNImmunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfallsArch Pathol Lab Med2014138679480224878018
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYKwakELEfficacy and safety of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer: updated results from the molecularly defined cohort of this first-in-man phase I studyLancet Oncol2012131011101922954507
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
   PubMed Web of Science ®Google Scholar
• CrinòLKimDRielyGJInitial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005J Clin Oncol201129suppl Abstr7514
   Google Scholar
• SørensenJBHansenHHHansenMBrain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosisJ Clin Oncol19886147414803047337
   PubMed Web of Science ®Google Scholar
• CostaDBShawATOuSHClinical experience with crizotinib in patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases in PROFILE 1005 and PROFILE 1007J Thorac Oncol20138suppl 2S294S295
   Google Scholar
• OttersonGARielyGJShawATClinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): potential implications for management [ASCO abstract 7600]J Clin Oncol20123015 suppl12
   Web of Science ®Google Scholar
• CostaDBKobayashiSPandyaSSCSF concentration of the anaplastic lymphoma kinase inhibitor crizotinibJ Clin Oncol20112915e443e44521422405
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged kung cancersSci Transl Med20124120120ra17
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in ALK gene rearranged non-small cell lung cancerClin Cancer Res2014181472148222235099
   PubMed Web of Science ®Google Scholar
• SasakiTKoivunenJOginoAA novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsCancer Res201171186051606021791641
   PubMed Web of Science ®Google Scholar
• ChoiYLSodaMYamashitaYALK Lung Cancer Study GroupEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
   PubMed Web of Science ®Google Scholar
• KimSKimTMKimDWHeterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancerJ Thorac Oncol20138441542223344087
   PubMed Web of Science ®Google Scholar
• MarsiljeTHPeiWChenBSynthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-Chloro-N2- (2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsJ Med Chem2013565675569023742252
   PubMed Web of Science ®Google Scholar
• FribouletLLiNKatayamaRThe ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerCancer Discovery2013412112
   Google Scholar
• ShawATKimD-WMehraRCeritinib in ALK-rearranged non-small-cell lung cancerN Engl J Med2014370131189119724670165
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationCeritinib2014 Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm395386.htmAccessed July 1, 2014
   Google Scholar
• KimDWMehraRTanDSWCeritinib in advanced anaplastic lymphoma kinase (ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trialJ Clin Oncol20143215, suppl 18078
   Web of Science ®Google Scholar
• TanDSWShawATMehraRCeritinib in Asian versus Caucasian patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: subgroup analysis of the ASCEND-1 trialJ Clin Oncol20143215, suppl 18078
   Web of Science ®Google Scholar
• CamidgeDRBazhenovaLSalgiaRUpdated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignanciesPaper presented at: European Cancer CongressSeptember 27–October 1; 2013Amsterdam, the Netherlands Abstract 3401
   Google Scholar
• SetoTKiuraKNishioMCH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyLancet Oncol20131459059823639470
   PubMed Web of Science ®Google Scholar
• KodamaTHasegawaMTakanashiKSakuraiYKondohOSakamotoHAntitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastasesCancer Chemother Pharmacol20147451023102825205428
   PubMed Web of Science ®Google Scholar
• SakamotoHTsukaguchiTHiroshimaSCH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutantCancer Cell20111967969021575866
   PubMed Web of Science ®Google Scholar
• KodamaTTsukaguchiTYoshidaMKondohOSakamotoHSelective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistanceCancer Lett201435121522124887559
   PubMed Web of Science ®Google Scholar
• AwadMMShawATALK Inhibitors in non-small cell lung cancer: crizotinib and beyondClin Adv Hematol Oncol201412742943925322323
   PubMedGoogle Scholar
• SangJAcquavivaJFriedlandJCTargeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerCancer Discovery20133443044323533265
   PubMed Web of Science ®Google Scholar
• DjalalovSBecaJHochJSCost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancerJ Clin Oncol2014321012101924567430
   PubMed Web of Science ®Google Scholar